CAR NK biotech Catamaran Bio to wind down, will seek partners for cell therapies Off-the-shelf cell therapy biotech Catamaran Bio made a “recent decision to commence wind-down,” CEO Alvin Shih told Endpoints News in an email on Monday. The Boston biotech will cease day-to-day operations and seek strategic partners for its CAR NK cell therapy candidates and technology, Shih wrote in a LinkedIn post on Monday. Catamaran had 19 employees as of Monday morning, he told Endpoints, and a “handful” will stay on for a transition period. Unlock this article instantly by becoming a free subscriber. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
This content was originally published here.